SELLAS Life Sciences Announces Poster Presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting
NEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a...
NEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a...
WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology...
YAVNE, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused...
NEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on...
Hukyndra® increases availability of high-concentration, low-volume, citrate-free presentations of adalimumabExclusive partnership between Alvotech and STADA in Europe includes Hukyndra® and...
Hukyndra® increases availability of high-concentration, low-volume, citrate-free presentations of adalimumabExclusive partnership between Alvotech and STADA in Europe includes Hukyndra® and...
BELTSVILLE, Md., Sept. 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...
– Impacting more than 12 million people globally, HDV is the most aggressive form of viral hepatitis – – Novel...
FLORHAM PARK, N.J., Sept. 22, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a...
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy...
• Upon closing of their proposed Business Combination, Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition...
-- Single agent Anti-PD1-IL-2 BiSKIT™ showed superior efficacy compared to a combination of an anti-PD1 antibody with an IL-2 Superkine...
Approximately 40% of Long COVID Patients Experience Multi-Site Pain Similar to Overlapping Chronic Pain Syndromes Fibromyalgia and ME/CFS Approximately 50%...
KRASG12C(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring KRASG12C mutation RMC-6291 is first...
WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
Initial CPRIT grant funds of $1.9 million to be disbursed to Company by October 31, 2022 CPRIT grant to support...
Testing Times Report reflects expert opinion that “Supporting more widespread use of rapid diagnostic technology should be a central aim...
Phase 1 clinical trial in patients with renal impairment demonstrates balixafortide to be safe and well tolerated Safety findings support...
- Presentation Scheduled for Wednesday, September 28 from 10:40-11:20 AM ET -SAN DIEGO and REDWOOD CITY, Calif., Sept. 21, 2022...
Launching the most ambitious and comprehensive health campaign in British Columbia’s historyOne in two British Columbians will face cancer in...